StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

Semaglutide

Semaglutide is a GLP-1 receptor agonist used for significant weight loss and glycemic control in individuals with obesity and type 2 diabetes. It is administered as a once-weekly injection and has shown efficacy in reducing body weight by 15-17% in clinical trials.

weight-lossmetabolicblood-sugarappetite
Evidence last reviewed: 19 Apr 2026
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on Semaglutide.
Biomarkers studied
Outcomes directly measured across the evidence records below
Metabolic
Body WeightBMIBlood Glucose
Evidence
5 records
Weight reduction
Adults with overweight or obesityRCT
PUBMEDHigh

Semaglutide resulted in a mean weight reduction of 11.85% compared to placebo.

Dose: 2 mgDuration: 68 weeksForm: Subcutaneous injectionTiming: Once weekly
Body weight reduction
Adults with overweight or obesityRCT
PUBMEDHigh

Semaglutide led to a 14.9% reduction in body weight compared to 2.4% with placebo.

Dose: 2 mgDuration: 68 weeksForm: Subcutaneous injectionTiming: Once weekly
Glycemic control
Adults with type 2 diabetesSystematic review and network meta-analysis
PUBMEDHigh

Semaglutide improved glycemic control and reduced body weight in type 2 diabetes patients.

Dose: 2 mgForm: Subcutaneous injectionTiming: Once weekly
Weight loss maintenance
Adults with overweight or obesity without diabetesRCT
PUBMEDHigh

Continued semaglutide use maintained weight loss, but withdrawal led to weight regain.

Dose: 2 mgDuration: 68 weeksForm: Subcutaneous injectionTiming: Once weekly
Cardiometabolic risk factors
Adults with obesity without diabetesSystematic review and meta-analysis
PUBMEDHigh

Semaglutide reduced cardiometabolic risk factors but increased gastrointestinal adverse events.

Dose: 2 mgForm: Subcutaneous injectionTiming: Once weekly
Forms
Subcutaneous injection
Administered once weekly, typically at a dose of 2.4 mg.

Stacks containing Semaglutide

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.